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Introduction
Bleomycin is an antineoplastic drug that causes DNA damage by intra-
and inter-strand crosslink and DNA strand breaks. This drug is used to
treat several types of cancers, including lymphoma, squamous cell
carcinoma of the cervix, head, and neck, and Hodgkin's disease.
Resistance to bleomycin is a major concern in the clinic.
Although the cellular and molecular mechanism of resistance to this
drug is not entirely clear, there are several possibilities for that this
phenomenon can occur: alteration of the cellular entry and exit of
bleomycin, higher repair capacity of DNA damage induced by
Bleomycin and increase in bleomycin inactivation metabolism.
Objectives
The aim of this work is to study the effect of Bleomycin on S. cerevisiae
cells and select bleomycin-resistant cells to study the process of
resistance acquisition to establish new protocols in in vitro drugs
exposure.
Methodology
Yeast strain and culture medium
The experiments were carried out with the haploid yeast strain
Saccharomyces cerevisiae WS8105-1C (MATalpha, ade2, arg4-17, trp1-
289, ura3-52). Yeast cells were grown in a solid medium of YPD for the
cytotoxicity assay, and in a liquid medium of YPD for selecting
bleomycin-resistant cells of this organism.
Chemicals
The antineoplastic drug used was bleomycin. The doses used were 0,
0,001, 0,003, 0,005, 0,008, 0,01, 0,03 y 0,06 UI/ml for the cytotoxicity
assay and for selecting bleomycin -resistant cells was 0,05 UI/ml in
cycle 1-5 and 0,158 UI/ml (ID 90) in cycle 6-7.
Experimental protocol
Cytotoxicity test: cells were added to test tubes with different doses of
bleomycin and they were completed with sterile water. Then, the tubes
were cultured during 24 hours at 30°C and cells washed twice with
sterile water. For drop test assay, six 10-fold serial dilutions from each
sample were prepared and five-microliter aliquots of each dilution were
spotted onto YPD plates.
Resistance selection: cells were added to test flask with liquid medium
of YPD and 0.05 UI/ml of bleomycin in cycle 1-5 and 0.158 UI/ml (ID
90) of bleomycin in cycle 6-7. Then, the flask were cultured during 15
days in orbital shaking at 300 rpm and at 30°C. Next, a reseeding was
carried out in another test flask with the same conditions. The process
was carried out seven times (seven cycles). The OD600 was measured
daily.
Results and conclusions
The cytotoxicity curve for bleomycin obtained by drop test
showed that the surviving fraction decreased gradually as
bleomycin dose increased in the wild strain S. cerevisiae (WT). The
ID50 and ID90 values obtained were 0.001 UI/ml and 0.158
UI/ml, respectively.
When WT was exposed to bleomycin doses, in the different
resistance cycles, it was obtained that in cycle 1 and for a N
value of 1.2E+8 cells/ml the stationary phase was reached on
day 14. In cycle 2 and for a N value of 9E+7 cells/ml the
stationary phase was reached on day 7. In cycle 3 and for a N
value of 1.1E+8 cells/ml the stationary phase was reached on
day 6. In cycles 4 and 5 and for a N value of 1.1E+8 cells / ml
the stationary phase was reached on day 5. In cycles 6 and 7
and for a N value of 1.25E+8 cells/ml the stationary phase was
reached on day 6.
In addition, there was a delay in cell growth. So, for a value of N
of 4E+7 cells/ml cycle1 presented a time of 9 days, cycle 2 of 6
days, cycle 3 of 5 days and cycles 4-7 of 2 days approximately.
Thus it was observed that for the same value of N, as more
cycles were done, the time to reach that value decreased.
The 7 cycles lasted 110 days. Cycle 1 that for a N value of
1.1E+8 cells/ml presented a time of 15 days, cycles 2-6 that for a
N value of 1.1E+8 cells/ml presented a time of 30, 47, 60, 80
and 96 days, respectively, and cycle 7 which, for a N value of
1.3E+8 cells/ml, presented a time of 110 days.
To confirm that the yeast acquired resistance, the same
cytotoxicity test was carried out. The decrease of the surviving
fraction in the WT was clearly greater than in strain WS8105-1C-R
0.158 Bleo (resistant strain). In addition, in the resistant strain the
ID50 and ID90 values obtained were 0.0156 UI/ml (15.6 times
more resistant with respect to the WT) and 2.818 UI/ml (17.83
times more resistant with respect to the WT), respectively.
In conclusion, at first cells were sensitive to the drug and had low
cell growth, but when cells were subjected to drug concentration
in each cycle, they developed resistance mechanisms that
allowed them to survive, grow and divide in the presence of
bleomycin, thus increasing cell growth. In addition, it could also
be observed that the stationary phase was reached in a shorter
time. These facts indicate the acquisition of resistance in only 7
cycles of exposure. The results indicate that continuous exposure
in only 2-7 cycles are enough to obtain high bleomycin
resistance, suggesting that new protocols of in vitro exposure
should take into account in future studies.
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